3,4-Dichloro-Phe-OMe.HClCAS# 270063-47-3 |
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Capsaicin
Catalog No.:BCN1016
CAS No.:404-86-4
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 270063-47-3 | SDF | Download SDF |
| PubChem ID | 2761633 | Appearance | Powder |
| Formula | C10H12Cl3NO2 | M.Wt | 284.57 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S)-3-amino-4-(2,4-dichlorophenyl)butanoic acid;hydrochloride | ||
| SMILES | C1=CC(=C(C=C1Cl)Cl)CC(CC(=O)O)N.Cl | ||
| Standard InChIKey | JNGZEMBEPQATGG-QRPNPIFTSA-N | ||
| Standard InChI | InChI=1S/C10H11Cl2NO2.ClH/c11-7-2-1-6(9(12)4-7)3-8(13)5-10(14)15;/h1-2,4,8H,3,5,13H2,(H,14,15);1H/t8-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
3,4-Dichloro-Phe-OMe.HCl Dilution Calculator
3,4-Dichloro-Phe-OMe.HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5141 mL | 17.5704 mL | 35.1407 mL | 70.2815 mL | 87.8518 mL |
| 5 mM | 0.7028 mL | 3.5141 mL | 7.0281 mL | 14.0563 mL | 17.5704 mL |
| 10 mM | 0.3514 mL | 1.757 mL | 3.5141 mL | 7.0281 mL | 8.7852 mL |
| 50 mM | 0.0703 mL | 0.3514 mL | 0.7028 mL | 1.4056 mL | 1.757 mL |
| 100 mM | 0.0351 mL | 0.1757 mL | 0.3514 mL | 0.7028 mL | 0.8785 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
3,4-Dichloro-Phe-OMe.HCl
- Lariciresinol
Catalog No.:BCN5158
CAS No.:27003-73-2
- Sphingosine-1-phosphate
Catalog No.:BCC7034
CAS No.:26993-30-6
- 16-Acetoxy-7-O-acetylhorminone
Catalog No.:BCN5157
CAS No.:269742-39-4
- Aglaxiflorin D
Catalog No.:BCN6594
CAS No.:269739-78-8
- Timolol Maleate
Catalog No.:BCC4340
CAS No.:26921-17-5
- H-D-Dab-OH.2HCl
Catalog No.:BCC3185
CAS No.:26908-94-1
- Fmoc-Orn(Dde)-OH
Catalog No.:BCC3534
CAS No.:269062-80-8
- Etravirine (TMC125)
Catalog No.:BCC5027
CAS No.:269055-15-4
- 2(-4-Chloro-3-hydroxy-1-butynyl)-5-1,(3-pentadiynyl)thiophene
Catalog No.:BCN1465
CAS No.:26905-70-4
- Oxysophocarpine
Catalog No.:BCN5156
CAS No.:26904-64-3
- 6-Hydroxybenzofuran-2(3H)-one
Catalog No.:BCN5155
CAS No.:2688-49-5
- Isomahanimbine
Catalog No.:BCN3175
CAS No.:26871-46-5
- 17-Hydroxy-1a,2a-methylenepregna-4,6-diene-3,20-dione acetate
Catalog No.:BCC8442
CAS No.:2701-50-0
- alpha-Hederin
Catalog No.:BCN5159
CAS No.:27013-91-8
- 2'-Methoxykurarinone
Catalog No.:BCN2986
CAS No.:270249-38-2
- H-D-Glu(OMe)-OMe.HCl
Catalog No.:BCC2941
CAS No.:27025-25-8
- Solasurine
Catalog No.:BCN2694
CAS No.:27028-76-8
- Paradol
Catalog No.:BCC1837
CAS No.:27113-22-0
- MMK 1
Catalog No.:BCC6037
CAS No.:271246-66-3
- Thevetin B
Catalog No.:BCN4046
CAS No.:27127-79-3
- 3-Tritylmercapto-Propionicacid
Catalog No.:BCC2846
CAS No.:27144-18-9
- SD-06
Catalog No.:BCC1937
CAS No.:271576-80-8
- Thonningianin A
Catalog No.:BCN2774
CAS No.:271579-11-4
- LY 393558
Catalog No.:BCC7660
CAS No.:271780-64-4
Evaluation of the (1,3)-beta-D-glucan assay for the diagnosis of neonatal invasive yeast infections.[Pubmed:28371838]
Med Mycol. 2018 Jan 1;56(1):78-87.
Most newborns in the neonatal intensive care unit (NICU) are premature and at risk of invasive fungal infections (IFIs). Invasive yeast infections (IYIs) are the most common fungal infections in this population. These infections are difficult to diagnose because symptoms are nonspecific, and the sensitivity of blood cultures is low. The serum (1,3)-beta-D-glucan (BDG) assay provides a reliable marker for the diagnosis of IFIs in adults with haematological malignancies. We assessed the diagnostic performance of this test in neonatal IYIs and its contribution to the monitoring of antifungal treatment. A retrospective study was performed in the NICU of the French University Hospital of Amiens from February 2012 to February 2014. Forty-seven neonates (33 males, 14 females) with a median gestational age of 30 weeks (IQR: 27-31) and median birth weight of 1200 g (IQR: 968-1700) were included and divided into three groups: 21 control neonates (CTRL), 20 neonates with probable IYI (PB), and six with proven IYI (PV). Median BDG levels were significantly higher in the global IYI group (PB + PV): 149 pg/ml (IQR: 85-364) vs. CTRL group: 39 pg/ml (IQR: 20-94) (P < .001). The optimal cut-off was 106 pg/ml (sensitivity 61.5%; specificity 81%). BDG levels decreased with antifungal treatment. BDG was detectable in cerebrospinal fluid, but the interest of this for diagnostic purposes remains unclear. Our results suggest that the BDG assay may be useful for the early identification of IYIs in neonates and for monitoring antifungal therapy efficacy.
Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.[Pubmed:28371666]
Cytokine. 2017 Aug;96:75-86.
BACKGROUND: Hepatocellular carcinoma (HCC) is the 6th most common cancer and the 3rd leading cause of cancer causing death allover the world. The aim of this research to explore the clinical relevance of blood angiopoietin-like protein-3 (ANGPTL3) and ANGPTL4 expression and their proteins levels as non invasive biomarkers in cirrhotic and HCC patients and their influence on the clinicopathological features of HCC. MATERIAL AND METHODS: This work comprised 200 patients with chronic hepatitis (120 cases complicated with cirrhosis, 80 patients with primary HCC) and 100 controls. circulating ANGPTL3 and ANGPTL4 expression was estimated by real-time polymerase chain reaction (RT-PCR). ANGPTL3 and ANGPTL4 protein levels were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: The circulating ANGPTL3 and ANGPTL 4 expression was significantly elevated in HCC cases compared to chronic hepatitis patients and controls. There were much more serum ANGPTL3 and ANGPTL4 values in HCC and chronic hepatitis patients as compared to controls, but we couldn't detect this significance between chronic hepatitis and HCC cases as regards ANGPTL4. By Multiple stepwise linear regression analysis, an increased ANGPTL3 expression, alpha-fetoprotein (AFP), serum ANGPTL 3 levels, Child-Pugh grade were significantly assosciatedassociated with increased risk of HCC. Logistic regression analysis revealed that ANGPTL 3 expression and AFP levels were the only pridectorspredictors of HCC (odd's ratio (OR)=8.9; 8.6 respectively, P=0.003). Receiver operator characteristic (ROC) demonsterated that serum ANGPTL3 and ANGPTL4 levels were usufuluseful biomarkers discriminating chronic hepatitis cases from controls (AUC=0.820,0.887, respectively P<0.001). However, they fail to discriminate HCC patients from chronic hepatitis patients (P=0.27,0.12 respectively). Moreover, ANGPTL3 and ANGPTL 4 expression were promising biomarkers discriminating chronic hepatitis cases from controls and those HCC cases from chronic hepatitis patients (P<0.001). Combined ANGPTL3 expression and serum level wasn't useful in discriminating HCC patient from chronic hepatitis (P=0.09). In contrast, combined ANGPTL4 expression and serum level was an useful biomarker discriminating HCC cases from chronic hepatitis. CONCLUSION: ANGPTL3 and ANGPTL 4 expression and serum levels can be promising non invasive biomarkers in diagnosis of chronic hepatitis and HCC especially their expression could be useful in discriminating HCC from chronic hepatitis patients.
Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives.[Pubmed:28371664]
Bioorg Chem. 2017 Jun;72:74-79.
In the present study, a series of fourteen 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives were designed, synthesized and characterized by appropriate spectral analysis. Further, titled compounds were in-vitro screened against wild HIV-1 RT enzyme using ELISA based colorimetric assay, in which four compounds significantly inhibited the RT activity with IC50
Analysis of Packet-Loss-Induced Distortion in View Synthesis Prediction-Based 3D Video Coding.[Pubmed:28371778]
IEEE Trans Image Process. 2017 Jun;26(6):2781-2796.
View synthesis prediction (VSP) is a crucial coding tool for improving compression efficiency in the next generation 3D video systems. However, VSP is susceptible to catastrophic error propagation when multi-view video plus depth (MVD) data are transmitted over lossy networks. This paper aims at accurately modeling the transmission errors propagated in the inter-view direction caused by VSP. Toward this end, we first study how channel errors gradually propagate along the VSP-based inter-view prediction path. Then, a new recursive model is formulated to estimate the expected end-to-end distortion caused by those channel losses. For the proposed model, the compound impact of the transmission distortions of both the texture video and depth map on the quality of the synthetic reference view is mathematically analyzed. Especially, the expected view synthesis distortion due to depth errors is characterized in the frequency domain using a new approach, which combines the energy densities of the reconstructed texture image and the channel errors. The proposed model also explicitly considers the disparity rounding operation invoked for the sub-pixel precision rendering of the synthesized reference view. Experimental results are presented to demonstrate that the proposed analytic model is capable of effectively modeling the channel-induced distortion for MVD-based 3D video transmission.
